Pediatric Glioma Registries Could Test ‘Product-Agnostic’ External Controls

 
• By Kate Rawson
  
The FDA wants to develop product-agnostic registries that could be external controls for diffuse midline glioma inclusive of diffuse intrinsic pontine glioma trials. (Shutterstock)

More from Real-World Evidence

More from United States